The variable phenotype of the p.A16V mutation of cationic trypsinogen (PRSS1) in pancreatitis families
Christopher Grocock(University of Liverpool), Louis J. Vitone(University of Liverpool), Michael Raraty(University of Liverpool), David C. Whitcomb(University of Pittsburgh), V. Rebours(Hôpital Beaujon), M. Harcus(University of Liverpool), E. Niemczyck(University of Liverpool), Maiken Thyregod Jørgensen(Odense University Hospital), W. Greenhalf(University of Liverpool), P. Burgess(Great Western Hospital), Ove B. Schaffalitzky de Muckadell(Odense University Hospital), Åke Andrén‐Sandberg(Karolinska Institutet), John P. Neoptolemos(University of Liverpool), Richard Charnley(Freeman Hospital), R. Mountford(University of Liverpool), Bronwyn Kerr(Manchester Academic Health Science Centre), Susie Dodd(University of Liverpool), Pierre Lévy(Hôpital Beaujon), Robert Sutton(University of Liverpool), Markus M. Lerch(Universitätsmedizin Greifswald), M. Delhaye(Erasmus Hospital), J. Devière(Erasmus Hospital), R Ammann(University College Dublin), Jane Butler(University of Liverpool)
Cited by 59
Related Papers
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
|The Lancet|2017|1.9k
Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene
|Nature Genetics|1996|1.6k
Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
|JAMA|2010|1.4k
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
|The Lancet Oncology|2019|1.2k
Chronic pancreatitis: Diagnosis, classification, and new genetic developments
|Gastroenterology|2001|1.2k